Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review

被引:28
作者
Formentini, A [1 ]
Henne-Bruns, D [1 ]
Kornmann, M [1 ]
机构
[1] Univ Ulm, Dept Visceral & Transplantat Surg, D-89075 Ulm, Germany
关键词
5-FU; colon cancer; fluoropyrimidines; gastric cancer; pancreatic cancer;
D O I
10.1007/s00423-004-0510-y
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background and aims: Many studies have been published that report an association between thymidylate synthase (TS) and response to fluoropyrimidine-based chemotherapy and the overall outcome of patients with gastrointestinal cancer. The results have given rise to the possibility that, by determination of TS levels, the physician may decide if the patient has a potential benefit from fluoropyrimidine-based treatment, similar to measurements of oestrogen receptors in breast cancer. The purpose of this review is to summarize critically the reports on TS measurement in gastrointestinal cancer, focusing on the adjuvant fluoropyrimidine treatment situation. Methods: We reviewed more than 20 studies that reported the association of TS with the clinical outcome in patients with gastrointestinal cancer who had undergone complete resection of the primary tumour only or were receiving additional adjuvant chemotherapy. Results: Patients with metastasized disease who expressed high TS levels display a low probability of responding to fluoropyrimidine-based treatment and have a poorer survival rate. Patients with high TS levels who undergo complete surgical resection of the primary tumour also have a poorer prognosis than those with tumours with low TS expression. In contrast to advanced disease and to surgery alone, patients with high TS levels appear to benefit, especially, from adjuvant fluoropyrimidine-based chemotherapy after complete primary tumour resection, while patients with low TS levels do not. Conclusion: Patients with gastrointestinal cancers that express high TS levels have a poor prognosis with regard to fluoropyrimidine-based palliative chemotherapy or complete primary tumour resection. In contrast, patients with high TS levels might benefit from adjuvant fluoropyrimidine-based treatment after primary tumour resection. However, additional prospective studies are mandatory to define the precise role of TS in adjuvant therapy.
引用
收藏
页码:405 / 413
页数:9
相关论文
共 68 条
[1]   Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer [J].
Allegra, CJ ;
Parr, AL ;
Wold, LE ;
Mahoney, MR ;
Sargent, DJ ;
Johnston, P ;
Klein, P ;
Behan, K ;
O'Connell, MJ ;
Levitt, R ;
Kugler, JW ;
Tirona, MT ;
Goldberg, RM .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (07) :1735-1743
[2]   Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer:: A national cancer institute-national surgical adjuvant breast and bowel project collaborative study [J].
Allegra, CJ ;
Paik, S ;
Colangelo, LH ;
Parr, AL ;
Kirsch, I ;
Kim, G ;
Klein, P ;
Johnston, PG ;
Wolmark, N ;
Wieand, HS .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (02) :241-250
[3]   Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].
Andre, T ;
Boni, C ;
Mounedji-Boudiaf, L ;
Navarro, M ;
Tabernero, J ;
Hickish, T ;
Topham, C ;
Zaninelli, M ;
Clingan, P ;
Bridgewater, J ;
Tabah-Fisch, I ;
de Gramont, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351
[4]  
Aschele C, 2000, CLIN CANCER RES, V6, P4797
[5]   Thymidylate Synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer [J].
Aschele, C ;
Lonardi, S ;
Monfardini, S .
CANCER TREATMENT REVIEWS, 2002, 28 (01) :27-47
[6]   2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology [J].
Bast, RC ;
Ravdin, P ;
Hayes, DF ;
Bates, S ;
Fritsche, H ;
Jessup, JM ;
Kemeny, N ;
Locker, GY ;
Mennel, RG ;
Somerfield, MR .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1865-1878
[7]  
Bathe OF, 1999, CANCER J SCI AM, V5, P34
[8]  
Berglund A, 2002, ANTICANCER RES, V22, P3653
[9]  
Bertino JR, 2003, CLIN CANCER RES, V9, P1235
[10]   Vascular endothelial growth factor expression, S-phase fraction and thymidylate synthase quantitation in node-positive colon cancer: Relationships with tumor recurrence and resistance to adjuvant chemotherapy [J].
Cascinu, S ;
Graziano, F ;
Valentini, M ;
Catalano, V ;
Giordani, P ;
Staccioli, MP ;
Rossi, C ;
Baldelli, AM ;
Grianti, C ;
Muretto, P ;
Catalano, G .
ANNALS OF ONCOLOGY, 2001, 12 (02) :239-244